Actively Recruiting
Phase IIb Study of Oral Pooled Fecal Microbiotherapy MaaT033 to Prevent Complications After Allogeneic Hematopoietic Cell Transplantation in Patients 50 Years and Older
Led by MaaT Pharma · Updated on 2024-12-27
387
Participants Needed
54
Research Sites
15 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the activity of an oral pooled fecal microbiotherapy called MaaT033 to prevent complications related to allogeneic hematopoietic cell transplantation alloHCT in patients aged 50 years and older with hematologic malignancies. This phase IIb randomized, placebo-controlled trial aims to improve overall survival by reducing transplant-related complications. The study is conducted by MaaT Pharma and includes a double-blinded design to compare the effects of the treatment against a placebo. Participants will receive either the oral pooled fecal microbiotherapy MaaT033 or a placebo in capsule form, with a dosage of three capsules per day. The study involves a reduced toxicity or reduced intensity conditioning regimen before alloHCT. The trial excludes patients receiving certain conditioning regimens or treatments, as well as those with specific medical conditions or infections. The treatment period spans the time around transplantation, with follow-up assessments planned to evaluate treatment effects. During the study, participants will be closely monitored for overall survival up to 12 months after alloHCT. Researchers will assess gut microbiota diversity restoration, incidence and severity of acute graft-versus-host disease GvHD, mortality causes, immune suppression therapy discontinuation, platelet and neutrophil engraftment times, severe infections, quality of life, and safety through adverse event monitoring. Study visits will include clinical evaluations, laboratory tests, and questionnaires to collect these data throughout the 12-month follow-up period.
CONDITIONS
Brief Title
Oral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Complications (PHOEBUS Trial)
Research Team
E
Emilie Plantamura, PharmD, PhD
R
Romain Collard
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here